Diana Ernst, RPh

Editorial Director https://www.cancertherapyadvisor.com

Diana Ernst, RPh, is the Editorial Director for MPR, part of the Haymarket Medical Network. Since 2003, Diana has worked to provide healthcare professionals with up-to-date drug information through MPR's print and digital offerings. She is a graduate of the Ernest Mario School of Pharmacy, Rutgers University.

All articles by Diana Ernst, RPh

Breast Cancer

Biosimilar Cancer Treatment Ontruzant Gets FDA Approval

Diana Ernst, RPh

January 22, 2019

Prior to treatment, HER2 testing using FDA-approved tests should be performed.

Lung Cancer

Tecentriq Combination Regimen Approved for Metastatic Non-Squamous NSCLC

Diana Ernst, RPh

December 11, 2018

The approval was based on data from the IMpower 150 trial, an open-label study involving 1202 patients with stage IV metastatic NSq NSCLC who had not received prior chemotherapy for metastatic disease, but could have received prior EGFR or ALK kinase inhibitor if appropriate, regardless of PD-L1 or T-effector gene status and ECOG performance status 0 or 1.

Next post in Lung Cancer

Diana Ernst, RPh

All articles by Diana Ernst, RPh

Biosimilar Cancer Treatment Ontruzant Gets FDA Approval

Tecentriq Combination Regimen Approved for Metastatic Non-Squamous NSCLC

Adjuvant Erlotinib May Benefit Patients With Early-Stage Non-Small Cell Lung Cancer